Get All Access for FREEMarket News & Research,
Live Transcripts & Audio,
and a whole lot more…
World's largest chemical company $DWDP reported a 4Q17 GAAP loss attributable to the company of $1.26Bil or $0.54 per share, driven by restructuring costs and write-down in asset values. Pro forma adjusted EPS, however, jumped 41% from a year ago. Correspondingly, revenue jumped 13% YoY, with net sales of $20.1Bil, helped by robust product demand.
$BHGE, a provider of oilfiled products and services, reported a net loss of $29MM or $0.07 per share in 4Q17. In the preceding quarter, the company had reported a loss of $0.24 per share. On a non-GAAP basis, Baker Hughes posted earnings of $0.15 per share in 4Q17. Total revenues were $5.76BIl, down 3% compared to the year-ago quarter.
$SSNC agreed to buy $DST in an all-cash transaction for $84 per share plus assumption of debt, equating to an enterprise value of about $5.4Bil. $SSNC plans to fund the acquisition and refinance existing debt with a combination of debt and equity. Both $SSNC's and $DST's BoD have approved the transaction, and it is expected to close by 3Q18.
$VVV, a producer of automotive lubricants, has appointed Brad Patrick as Chief People and Communications Officer. Patrick, who joins the company from Tempur Sealy International, will report to Valvoline's CEO Sam Mitchell. Previously, Patrick held key HR positions at Sara Lee, The Gillette, Delta Air Lines and Frito-Lay.
Business advisory firm $FCN has appointed Jan Naifeh as Senior Managing Director of its Corporate Finance & Restructuring segment. Most recently, Naifeh served SunTrust Bank as SVP of the Corporate and Investment Banking Special Assets Division. The appointment is part of FTI’s continuing investment in its healthcare industry expertise.
$FCN announced the appointment of Elliot Sloane, former CEO and founder of Sloane & Company, as a Senior Managing Director in the firm’s Strategic Communications segment. Mr. Sloane will report to Brian Kennedy, the segment’s Head of the Americas.
Biotechnology company $BIVV said results of the latest study conducted on its class monoclonal antibody BIVV009, indicated for the treatment of cold agglutinin disease, achieved the primary and secondary endpoints. The endpoints included tolerability, pharmacokinetic profile supporting biweekly dosing, and classical complement pathway inhibition.
$BIVV and Swedish Orphan Biovitrum AB said new data showed that individualized dosing with extended half-life therapy, Alprolix, every 14 or more days may be a potential option for people with severe hemophilia B who seek the benefits of protection from a prophylactic therapy with reduced treatment burden.
$AOBC now sees 3Q18 net sales of $170-180MM generating a GAAP EPS of $0.01-0.04 and adjusted EPS of $0.07-0.10. For FY18, the firearm maker expects net sales of $650-675MM generating a GAAP EPS of $0.33-0.43 and adjusted EPS of $0.57-0.67.
With wholesaler and retailer orders slumping, iconic Smith & Wesson firearm maker $AOBC saw quarterly net sales slump 36% to $148.4MM in 2Q18. Net income reduced to a measly $3.2MM or $0.06 per diluted share, about one-tenth f om last year's $32.5MM or $0.57 per diluted share.